[ CAS No. 150374-99-5 ] {[proInfo.proName]}

Name: 150374-99-5|4-(Chlorosulfonyl)phenyl pivalate|95%
Brand: Ambeed
SKU: A220665
Price: 52.0 USD
Availability: InStock
Rating: 99 (25 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

2D 3D

Structure of 150374-99-5 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 150374-99-5 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 150374-99-5 ]

SDS Specification

Alternatived Products of [ 150374-99-5 ]

Product Details of [ 150374-99-5 ]

CAS No. :	150374-99-5	MDL No. :	MFCD08274725
Formula :	C₁₁H₁₃ClO₄S	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	BSRSTUAZWZWGRT-UHFFFAOYSA-N
M.W :	276.74	Pubchem ID :	11011277
Synonyms :

Calculated chemistry of [ 150374-99-5 ]

Physicochemical Properties

Num. heavy atoms :	17
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.36
Num. rotatable bonds :	4
Num. H-bond acceptors :	4.0
Num. H-bond donors :	0.0
Molar Refractivity :	65.19
TPSA :	68.82 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	Yes
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.79 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.54
Log Po/w (XLOGP3) :	3.1
Log Po/w (WLOGP) :	3.65
Log Po/w (MLOGP) :	2.31
Log Po/w (SILICOS-IT) :	1.98
Consensus Log Po/w :	2.71

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-3.51
Solubility :	0.0863 mg/ml ; 0.000312 mol/l
Class :	Soluble
Log S (Ali) :	-4.21
Solubility :	0.0169 mg/ml ; 0.0000612 mol/l
Class :	Moderately soluble
Log S (SILICOS-IT) :	-3.84
Solubility :	0.0404 mg/ml ; 0.000146 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	1.0 alert
Leadlikeness :	0.0
Synthetic accessibility :	2.02

Safety of [ 150374-99-5 ]

Signal Word:	Danger	Class:	8
Precautionary Statements:	P260-P280-P303+P361+P353-P301+P330+P331-P304+P340+P310-P305+P351+P338+P310	UN#:	3261
Hazard Statements:	H314	Packing Group:	Ⅲ
GHS Pictogram:

Application In Synthesis of [ 150374-99-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 150374-99-5 ]
Downstream synthetic route of [ 150374-99-5 ]

[ 150374-99-5 ] Synthesis Path-Upstream 1~6

1
[ 3282-30-2 ]
[ 825-90-1 ]
[ 150374-99-5 ]

Yield	Reaction Conditions	Operation in experiment
81.1%	Stage #1: With triethylamine In dichloromethane at 20 - 25℃; for 2.08333 h; Stage #2: With thionyl chloride In N,N-dimethyl-formamide at 20 - 25℃; for 2.25 h;	Sodium 4-hydroxybenzenesulfonate (3) (1.0 g, 0.0049 mol),Addition of a solution of DCM (6 ml) and TEA (1.0 g, 0.0098 mol) in pivaloyl chloride (0.84 g, 0.0069 mol) is carried out dropwise at 20-25 ° C. under magnetic stirring in about 5 minutes. The mixtureContinue stirring at 20-25 ° C for 2 hours while monitoring with HPLC. After completion of the reaction,DMF (0.11 g, 0.0015 mol) was added,Thionyl chloride (0.77 g, 0.0064 mol) is added dropwise at 20-25 ° C. over 15 minutes. The mixtureWhile monitoring by HPLC,Stirring is continued for 2 hours at this temperature. After completion of the reaction,The solvent was removed by evaporation under reduced pressure,Toluene (10 ml) was added,The salt was filtered off,The solvent is concentrated under reduced pressure. To the resulting residue,5 ml of n-hexane was added,next,It was cooled to 0 ° C.,The resulting suspension is filtered,Wash the product with n-hexane. 1.1 g of a pale yellow solid (81.1percent).

Reference： [1] Patent: JP5746484, 2015, B2, . Location in patent: Paragraph 0003; 0006; 0009; 0015; 0036; 0037

2
[ 4920-92-7 ]
[ 150374-99-5 ]

Reference： [1] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 5, p. 1123 - 1134

3
[ 825-90-1 ]
[ 150374-99-5 ]

Reference： [1] Bioorganic and Medicinal Chemistry, 1996, vol. 4, # 12, p. 2115 - 2134
[2] Patent: JP5746484, 2015, B2,
[3] Journal of Organic Chemistry, 2018, vol. 83, # 8, p. 4323 - 4335

4
[ 108-95-2 ]
[ 150374-99-5 ]

Reference： [1] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 5, p. 1123 - 1134

5
[ 7065-46-5 ]
[ 150374-99-5 ]

Reference： [1] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 5, p. 1123 - 1134

6
[ 3282-30-2 ]
[ 150374-99-5 ]

Reference： [1] Patent: JP5746484, 2015, B2,

[ 150374-99-5 ] Synthesis Path-Downstream 1~84

1
[ 110-91-8 ]
[ 150374-99-5 ]
2,2-Dimethyl-propionic acid 4-(morpholine-4-sulfonyl)-phenyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

2
[ 288-32-4 ]
[ 150374-99-5 ]
2,2-Dimethyl-propionic acid 4-(imidazole-1-sulfonyl)-phenyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

3
[ 5344-90-1 ]
[ 150374-99-5 ]
2,2-Dimethyl-propionic acid 4-(2-hydroxymethyl-phenylsulfamoyl)-phenyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

4
[ 119-68-6 ]
[ 150374-99-5 ]
[ 188115-02-8 ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

5
[ 19008-43-6 ]
[ 150374-99-5 ]
4-[4-(2,2-Dimethyl-propionyloxy)-benzenesulfonylamino]-benzoic acid benzyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

6
[ 6303-99-7 ]
[ 150374-99-5 ]
2,2-Dimethyl-propionic acid 4-[2-(2-carboxy-ethoxy)-phenylsulfamoyl]-phenyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

7
[ 82185-41-9 ]
[ 150374-99-5 ]
2-[4-(2,2-Dimethyl-propionyloxy)-benzenesulfonylamino]-benzoic acid benzyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

8
[ 156674-65-6 ]
[ 150374-99-5 ]
4-{2-[4-(2,2-Dimethyl-propionyloxy)-benzenesulfonylamino]-phenoxy}-butyric acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

9
[ 80787-43-5 ]
[ 150374-99-5 ]
3-[4-(2,2-Dimethyl-propionyloxy)-benzenesulfonylamino]-benzoic acid benzyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

10
[ 112626-34-3 ]
[ 150374-99-5 ]
2,2-Dimethyl-propionic acid 4-{2-[(carboxymethyl-carbamoyl)-methyl]-phenylsulfamoyl}-phenyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

11
[ 75-64-9 ]
[ 150374-99-5 ]
2,2-Dimethyl-propionic acid 4-tert-butylsulfamoyl-phenyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

12
[ 100-61-8 ]
[ 150374-99-5 ]
2,2-Dimethyl-propionic acid 4-(methyl-phenyl-sulfamoyl)-phenyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

13
(2S)-N-(o-aminobenzoyl)-2-methylaminoacetic acid [ No CAS ]
[ 150374-99-5 ]
2,2-Dimethyl-propionic acid 4-[2-(carboxymethyl-methyl-carbamoyl)-phenylsulfamoyl]-phenyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

14
[ 150374-99-5 ]
1-(2-Amino-benzoyl)-piperidine-4-carboxylic acid [ No CAS ]
1-{2-[4-(2,2-Dimethyl-propionyloxy)-benzenesulfonylamino]-benzoyl}-piperidine-4-carboxylic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

15
[ 150374-99-5 ]
(4-Amino-benzoylamino)-acetic acid benzyl ester [ No CAS ]
2,2-Dimethyl-propionic acid 4-[4-(benzyloxycarbonylmethyl-carbamoyl)-phenylsulfamoyl]-phenyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

16
[ 150374-99-5 ]
benzyl 2-(2-aminobenzamido)acetate [ No CAS ]
[ 150374-98-4 ]

Yield	Reaction Conditions	Operation in experiment
89.5%	With pyridine; In dichloromethane; at 20 - 25℃; for 3.5h;	Benzyl 2- (2-aminobenzamido) acetate (10) (1.4 g, 0.0049 mol) prepared according to Example 8 was dissolved in dichloromethane (9 ml) and pyridine(1.2 g, 0.015 mol)Of the suspension,4- (chlorosulfonyl) phenyl (6) pivalate prepared according to Example 4(1.4 g, 0.0049 mol) in dichloromethane (7 ml)At 20 to 25 C. in about 30 minutes. The mixtureWhile monitoring by HPLC,Stirring is continued for 3 hours. After completion of the reaction,Water (10 ml) was added,Separate the phases. The organic phase was washed with waternext,Wash with 10% hydrochloric acid (10 ml) and saturated aqueous NaCl solution (10 ml). The mixture was crystallized from isopropyl ether (10 ml)Filtered,Dry at 40 C under reduced pressure. 2.3 g (89.5%) of a white solid are obtained.

Reference： [1]Patent: JP5746484,2015,B2 .Location in patent: Paragraph 0003; 0015; 0052; 0053; 0054
[2]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

17
[ 150374-99-5 ]
(3-Amino-benzoylamino)-acetic acid benzyl ester [ No CAS ]
2,2-Dimethyl-propionic acid 4-[3-(benzyloxycarbonylmethyl-carbamoyl)-phenylsulfamoyl]-phenyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

18
[ 150374-99-5 ]
4-(2-Amino-benzoylamino)-butyric acid benzyl ester [ No CAS ]
4-{2-[4-(2,2-Dimethyl-propionyloxy)-benzenesulfonylamino]-benzoylamino}-butyric acid benzyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

19
[ 150374-99-5 ]
3-(2-Amino-benzoylamino)-propionic acid benzyl ester [ No CAS ]
2,2-Dimethyl-propionic acid 4-[2-(2-benzyloxycarbonyl-ethylcarbamoyl)-phenylsulfamoyl]-phenyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

20
[ 150374-99-5 ]
6-(2-Amino-benzoylamino)-hexanoic acid benzyl ester [ No CAS ]
6-{2-[4-(2,2-Dimethyl-propionyloxy)-benzenesulfonylamino]-benzoylamino}-hexanoic acid benzyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

21
p-pivaloyloxybenzenesulfonic acid sodium salt [ No CAS ]
[ 150374-99-5 ]

Yield	Reaction Conditions	Operation in experiment
81.6%	With thionyl chloride; In N,N-dimethyl-formamide; at 5 - 20℃; for 1.5h;	(5) (1.5 g, 0.0054 mol) of 4- (pivaloyloxy) benzenesulfonate prepared according to Example 1,(0.78 g, 0.0065 mol) in DMF (7 ml) is added dropwise over 5 min at 0-5 C. The mixture is monitored by HPLC and the reaction is carried out at this temperature After completion of the reaction, water (10 ml) was added, and the mixture was filtered, washed thoroughly with water, and then dried under reduced pressure at 16 C. for 15 minutes at 45 C. The reaction mixture was stirred for 1 hour, Drying over time gives 1.2 g (81.6%) of a white solid.

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134
[2]Synthetic Communications,2008,vol. 38,p. 1718 - 1724
[3]Patent: JP5746484,2015,B2 .Location in patent: Paragraph 0003; 0006; 0009; 0032; 0033
[4]Journal of Organic Chemistry,2018,vol. 83,p. 4323 - 4335

22
[ 98-52-2 ]
[ 150374-99-5 ]
4-tert-butylcyclohexyl p-pivaloyloxybenzenesulfonate [ No CAS ]

Reference： [1]Synthetic Communications,2001,vol. 31,p. 2795 - 2802

23
[ 57-88-5 ]
[ 150374-99-5 ]
5-cholesten-3β-yl (p-pivaloyloxybenzenesulfonate) [ No CAS ]

Reference： [1]Synthetic Communications,2001,vol. 31,p. 2795 - 2802

24
[ 150374-99-5 ]
[ 582-52-5 ]
1,2:5,6-di-O-isopropylidene-3-O-(p-pivaloyloxybenzenesulfonyl)-α-D-glucofuranose [ No CAS ]

Reference： [1]Synthetic Communications,2001,vol. 31,p. 2795 - 2802

25
[ 150374-99-5 ]
(+)-N-benzyloxy-5,6,7,8-tetrahydropyrido[3,4-b]pyrazine-7-carboxamide hydrochloride [ No CAS ]
(+)-N-benzyloxy-6-(4-pivaloyloxybenzenesulfonyl)-5,6,7,8-tetrahydropyrido[3,4-b]pyrazine-7-carboxamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2003,vol. 11,p. 433 - 450

26
[ 150374-99-5 ]
{(3aR,5R,6S,6aR)-2,2-Dimethyl-6-[((Z)-propenyl)oxy]-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl}-methanol [ No CAS ]
1,2-O-isopropylidene-5-O-(p-pivaloyloxyphenylsulfonyl)-3-O-(prop-1'-enyl)-α-D-xylofuranose [ No CAS ]

Reference： [1]European Journal of Organic Chemistry,2002,p. 2377 - 2384

27
[ 150374-99-5 ]
[ 43138-65-4 ]
1,2-O-isopropylidene-3-O-methyl-6-O-(p-pivaloyloxyphenylsulfonyl)-α-D-glucofuranose [ No CAS ]

Reference： [1]European Journal of Organic Chemistry,2002,p. 2377 - 2384

28
[ 150374-99-5 ]
[ 473734-65-5 ]
1,2-O-isopropylidene-3-O-methyl-6-O-(p-pivaloyloxyphenylsulfonyl)-5-O-(prop-1'-enyl)-α-D-glucofuranose [ No CAS ]

Reference： [1]European Journal of Organic Chemistry,2002,p. 2377 - 2384

29
[ 150374-99-5 ]
5-O-(p-hydroxyphenylsulfonyl)-1,2-O-isopropylidene-3-O-(prop-1'-enyl)-α-D-xylofuranose [ No CAS ]

Reference： [1]European Journal of Organic Chemistry,2002,p. 2377 - 2384

30
[ 150374-99-5 ]
5-O-(p-tert-butyldimethylsilyloxyphenylsulfonyl)-1,2-O-isopropylidene-3-O-(prop-1'-enyl)-α-D-xylofuranose [ No CAS ]

Reference： [1]European Journal of Organic Chemistry,2002,p. 2377 - 2384

31
[ 150374-99-5 ]
(3'R,4'S)-5-O-(p-hydroxyphenylsulfonyl)-1,2-O-isopropylidene-3-O-(3'-methyl-2'-oxoazetidin-4'-yl)-α-D-xylofuranose [ No CAS ]

Reference： [1]European Journal of Organic Chemistry,2002,p. 2377 - 2384

32
[ 150374-99-5 ]
(3'S,4'R)-5-O-(p-hydroxyphenylsulfonyl)-1,2-O-isopropylidene-3-O-(3'-methyl-2'-oxoazetidin-4'-yl)-α-D-xylofuranose [ No CAS ]

Reference： [1]European Journal of Organic Chemistry,2002,p. 2377 - 2384

33
[ 150374-99-5 ]
(3'R,4'S)-1,2-O-isopropylidene-3-O-(3'-methyl-2'-oxoazetidin-4'-yl)-5-O-(p-pivaloyloxyphenylsulfonyl)-α-D-xylofuranose [ No CAS ]

Reference： [1]European Journal of Organic Chemistry,2002,p. 2377 - 2384

34
[ 150374-99-5 ]
(3'S,4'R)-1,2-O-isopropylidene-3-O-(3'-methyl-2'-oxoazetidin-4'-yl)-5-O-(p-pivaloyloxyphenylsulfonyl)-α-D-xylofuranose [ No CAS ]

Reference： [1]European Journal of Organic Chemistry,2002,p. 2377 - 2384

35
[ 150374-99-5 ]
(3'R,4'S)-5-O-(p-tert-butyldimethylsilyloxyphenylsulfonyl)-1,2-O-isopropylidene-3-O-(3'-methyl-2'-oxoazetidin-4'-yl)-α-D-xylofuranose [ No CAS ]

Reference： [1]European Journal of Organic Chemistry,2002,p. 2377 - 2384

36
[ 150374-99-5 ]
(3'S,4'R)-5-O-(p-tert-butyldimethylsilyloxyphenylsulfonyl)-1,2-O-isopropylidene-3-O-(3'-methyl-2'-oxoazetidin-4'-yl)-α-D-xylofuranose [ No CAS ]

Reference： [1]European Journal of Organic Chemistry,2002,p. 2377 - 2384

37
[ 150374-99-5 ]
[ 381704-81-0 ]

Reference： [1]Synthetic Communications,2001,vol. 31,p. 2795 - 2802

38
[ 150374-99-5 ]
[ 381704-90-1 ]

Reference： [1]Synthetic Communications,2001,vol. 31,p. 2795 - 2802

39
[ 3282-30-2 ]
3β-hydroxy-5α-cholestanone-(7) [ No CAS ]
[ 150374-99-5 ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

40
[ 825-90-1 ]
[ 150374-99-5 ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134
[2]Patent: JP5746484,2015,B2
[3]Journal of Organic Chemistry,2018,vol. 83,p. 4323 - 4335

41
[ 150374-99-5 ]
3-[4-(2,2-Dimethyl-propionyloxy)-benzenesulfonylamino]-benzoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

42
[ 150374-99-5 ]
4-[4-(2,2-Dimethyl-propionyloxy)-benzenesulfonylamino]-benzoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

43
[ 150374-99-5 ]
2-[4-(2,2-Dimethyl-propionyloxy)-benzenesulfonylamino]-benzoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

44
[ 150374-99-5 ]
[ 188115-03-9 ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

45
[ 150374-99-5 ]
[ 127373-66-4 ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134
[2]Patent: JP5746484,2015,B2

46
[ 150374-99-5 ]
2,2-Dimethyl-propionic acid 4-[2-(2-carboxy-ethylcarbamoyl)-phenylsulfamoyl]-phenyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

47
[ 150374-99-5 ]
2,2-Dimethyl-propionic acid 4-[3-(carboxymethyl-carbamoyl)-phenylsulfamoyl]-phenyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

48
[ 150374-99-5 ]
2,2-Dimethyl-propionic acid 4-[4-(carboxymethyl-carbamoyl)-phenylsulfamoyl]-phenyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

49
[ 150374-99-5 ]
4-{2-[4-(2,2-Dimethyl-propionyloxy)-benzenesulfonylamino]-benzoylamino}-butyric acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

50
[ 150374-99-5 ]
2,2-Dimethyl-propionic acid 4-[2-(carboxymethyl-carbamoyl)-phenyl]-methyl-sulfamoyl}-phenyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

51
[ 150374-99-5 ]
6-{2-[4-(2,2-Dimethyl-propionyloxy)-benzenesulfonylamino]-benzoylamino}-hexanoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

52
[ 150374-99-5 ]
[ 188115-04-0 ]

Reference： [1]Bioorganic and Medicinal Chemistry,1996,vol. 4,p. 2115 - 2134

Yield	Reaction Conditions	Operation in experiment
		REFERENCE EXAMPLE 5 p-pivaloyloxybenzenesulfonyl chloride STR66 Thionyl chloride (2.1 ml) was added to dimethylformamide solution (33 ml) of the compound (2.8 g) of Reference Example 4, and the mixture was stirred for 30 minutes under cooling with ice, and stirred for 30 minutes at room temperature. The reaction solution was extracted with ether-hexane (1:1), and the extract was washed twice with ice-water. The solution was dried with magnesium sulfate to give the title compound (2.49 g) having the following physical data. TLC Rf 0.34 (hexane: ethyl acetate =10: 1).

54
[ 5973-34-2 ]
[ 150374-99-5 ]
[ 1094231-79-4 ]

Reference： [1]Synthetic Communications,2008,vol. 38,p. 1718 - 1724

55
[ 526-21-6 ]
[ 150374-99-5 ]
[ 127373-66-4 ]

Reference： [1]Synthetic Communications,2008,vol. 38,p. 1718 - 1724
[2]Patent: WO2018/195486,2018,A1 .Location in patent: Sheet 12/33

56
[ 90610-21-2 ]
[ 150374-99-5 ]
2-hydroxyethyl 2-(4-(pivaloyloxy)phenylsulfonamido)benzoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	at 20℃; for 4h;	To a solution of isoatic anhydride (1 mmol) in terahydrofuran(THF, 5 mL) were added ethylene glycol (1.5 mmol) and DMAP(1.0 mmol), the mixture was stirred at 75 C for 12 h. The resultingsolution was concentrated in vacuum to yield a crude residuewhich was purified by chromatography on silica gel (acetone/hexane= 1:4) to provide intermediate 2-hydroxyethyl-2-aminobenzoate.The intermediate was reacted with 4-(chlorosulfonyl)phenylpivalate (2 mmol), which obtaining as Scheme 1 described, wasadded slowly at room temperature, then; the mixture was stirredat same temperature for 4 h. The resulting solution was concentrated and purified by chromatography on silica gel (acetone/hexane= 1:1) to furnish 23 (38%, Scheme 8),

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

57
[ 108-95-2 ]
[ 150374-99-5 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

58
[ 61485-11-8 ]
[ 150374-99-5 ]
4-(N-(2-pentanoylphenyl)sulfamoyl)phenyl pivalate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With pyridine; at 20℃; for 4h;	General procedure: Initially, phenol (10 mmol) was dissolved in acetonitrile. Themixture solution was slowly added 3,3-dimethylbutyryl chloride(1.5 equiv) at 0 C, and then stirred at room temperature for 12 h.The solvent was evaporated at reduced pressure. The residue waspurified by silica gel column chromatography using a mixture ofn-hexane and acetone to afford the phenyl pivalate. Subsequently,phenyl pivalate was dissolved in acetonitrile. The mixture solutionwas slowly added chlorosulfonic acid (1.5 equiv) at 0 C andreacted at 0 C for 15 min, and then refluxed at 75 C for 2 h. Thesolutions were quenched by ice; the resulting mixtures were filtrated;and the residues was purified by silica gel column chromatographyusing a mixture of n-hexane/ethyl acetate to afford<strong>[150374-99-5]4-(chlorosulfonyl)phenyl pivalate</strong> (Scheme 1). To a mixture solutionof 2-aminoacetophenone, 1-(2-aminophenyl)propan-1-one,1-(2-aminophenyl)butan-1-one, 1-(2-aminophenyl)pentan-1-one,or 2-aminobenzaldehyde (each 1.0 equiv) in pyridine, respectively,was added <strong>[150374-99-5]4-(chlorosulfonyl)phenyl pivalate</strong>, and then stirred atroom temperature for 4 h. The reaction mixture was concentratedand purified by silica gel column chromatography using a mixtureof n-hexane/acetone solutions, to afford the products (Scheme 2,1-5).

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

59
[ 2034-40-4 ]
[ 150374-99-5 ]
4-(N-(2-butyrylphenyl)sulfamoyl)phenyl pivalate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With pyridine; at 20℃; for 4h;	General procedure: Initially, phenol (10 mmol) was dissolved in acetonitrile. Themixture solution was slowly added 3,3-dimethylbutyryl chloride(1.5 equiv) at 0 C, and then stirred at room temperature for 12 h.The solvent was evaporated at reduced pressure. The residue waspurified by silica gel column chromatography using a mixture ofn-hexane and acetone to afford the phenyl pivalate. Subsequently,phenyl pivalate was dissolved in acetonitrile. The mixture solutionwas slowly added chlorosulfonic acid (1.5 equiv) at 0 C andreacted at 0 C for 15 min, and then refluxed at 75 C for 2 h. Thesolutions were quenched by ice; the resulting mixtures were filtrated;and the residues was purified by silica gel column chromatographyusing a mixture of n-hexane/ethyl acetate to afford<strong>[150374-99-5]4-(chlorosulfonyl)phenyl pivalate</strong> (Scheme 1). To a mixture solutionof 2-aminoacetophenone, 1-(2-aminophenyl)propan-1-one,1-(2-aminophenyl)butan-1-one, 1-(2-aminophenyl)pentan-1-one,or 2-aminobenzaldehyde (each 1.0 equiv) in pyridine, respectively,was added <strong>[150374-99-5]4-(chlorosulfonyl)phenyl pivalate</strong>, and then stirred atroom temperature for 4 h. The reaction mixture was concentratedand purified by silica gel column chromatography using a mixtureof n-hexane/acetone solutions, to afford the products (Scheme 2,1-5).

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

60
[ 1196-28-7 ]
[ 150374-99-5 ]
4-(N-(2-propionylphenyl)sulfamoyl)phenyl pivalate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With pyridine; at 20℃; for 4h;	General procedure: Initially, phenol (10 mmol) was dissolved in acetonitrile. Themixture solution was slowly added 3,3-dimethylbutyryl chloride(1.5 equiv) at 0 C, and then stirred at room temperature for 12 h.The solvent was evaporated at reduced pressure. The residue waspurified by silica gel column chromatography using a mixture ofn-hexane and acetone to afford the phenyl pivalate. Subsequently,phenyl pivalate was dissolved in acetonitrile. The mixture solutionwas slowly added chlorosulfonic acid (1.5 equiv) at 0 C andreacted at 0 C for 15 min, and then refluxed at 75 C for 2 h. Thesolutions were quenched by ice; the resulting mixtures were filtrated;and the residues was purified by silica gel column chromatographyusing a mixture of n-hexane/ethyl acetate to afford<strong>[150374-99-5]4-(chlorosulfonyl)phenyl pivalate</strong> (Scheme 1). To a mixture solutionof 2-aminoacetophenone, 1-(2-aminophenyl)propan-1-one,1-(2-aminophenyl)butan-1-one, 1-(2-aminophenyl)pentan-1-one,or 2-aminobenzaldehyde (each 1.0 equiv) in pyridine, respectively,was added <strong>[150374-99-5]4-(chlorosulfonyl)phenyl pivalate</strong>, and then stirred atroom temperature for 4 h. The reaction mixture was concentratedand purified by silica gel column chromatography using a mixtureof n-hexane/acetone solutions, to afford the products (Scheme 2,1-5).

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

61
[ 551-93-9 ]
[ 150374-99-5 ]
4-(N-(2-acetylphenyl)sulfamoyl)phenyl pivalate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
89%	With pyridine; at 20℃; for 4h;	A. Preparation of 4-(N-(2-acetylphenyl)sulfamoyl)phenyl pivalate (0101) 2-Aminoacetophenone (1 mmol) and <strong>[150374-99-5]p-pivaloyloxybenzenesulfonyl chloride</strong> (1.5 equivalent weights) were added into pyridine (5 mL) to obtain a mixture, followed by subjecting to reaction at room temperature for 4 hours and then removing pyridine under vacuum to obtain a reaction product. The reaction product was purified using a silica gel column (n-hexane/acetone=4:1), thereby obtaining 4-(N-(2-acetylphenyl)sulfamoyl)phenyl pivalate (331 mg, yield 89%).
	With pyridine; at 20℃; for 4h;	General procedure: Initially, phenol (10 mmol) was dissolved in acetonitrile. Themixture solution was slowly added 3,3-dimethylbutyryl chloride(1.5 equiv) at 0 C, and then stirred at room temperature for 12 h.The solvent was evaporated at reduced pressure. The residue waspurified by silica gel column chromatography using a mixture ofn-hexane and acetone to afford the phenyl pivalate. Subsequently,phenyl pivalate was dissolved in acetonitrile. The mixture solutionwas slowly added chlorosulfonic acid (1.5 equiv) at 0 C andreacted at 0 C for 15 min, and then refluxed at 75 C for 2 h. Thesolutions were quenched by ice; the resulting mixtures were filtrated;and the residues was purified by silica gel column chromatographyusing a mixture of n-hexane/ethyl acetate to afford<strong>[150374-99-5]4-(chlorosulfonyl)phenyl pivalate</strong> (Scheme 1). To a mixture solutionof 2-aminoacetophenone, 1-(2-aminophenyl)propan-1-one,1-(2-aminophenyl)butan-1-one, 1-(2-aminophenyl)pentan-1-one,or 2-aminobenzaldehyde (each 1.0 equiv) in pyridine, respectively,was added <strong>[150374-99-5]4-(chlorosulfonyl)phenyl pivalate</strong>, and then stirred atroom temperature for 4 h. The reaction mixture was concentratedand purified by silica gel column chromatography using a mixtureof n-hexane/acetone solutions, to afford the products (Scheme 2,1-5).

Reference： [1]Patent: US9073833,2015,B1 .Location in patent: Page/Page column 11-12
[2]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

62
[ 49667-81-4 ]
[ 150374-99-5 ]
4-(N-(2-(2-hydroxyethylcarbamoyl)phenyl)sulfamoyl)phenyl pivalate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With pyridine; In dichloromethane; at 20℃; for 4h;	To a solution of isoatic anhydride (1 mmol) in terahydrofuran(THF, 5 mL) were added ethylanolamine (1.5 mmol), and the mixturewas stirred at room temperature for 12 h. The resulting solutionwas concentrated in vacuum to yield a crude residue whichwas purified by chromatography on silica gel (acetone/hexane= 1:1) to provide intermediate 2-amino-N-(2-hydroxyethyl)benzamide. The intermediate (0.2 mmol) was dissolved in10% pyridine/DCM solution (5 mL), and 4-(chlorosulfonyl)phenylpivalate, which obtaining as Scheme 1 described, was added slowlyat room temperature, then; the mixture was stirred at same temperaturefor 4 h. The resulting solution was concentrated and purifiedby chromatography on silica gel (acetone/hexane = 1:1) tofurnish 22 (yielding 72%, Scheme 8),

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

63
[ 529-23-7 ]
[ 150374-99-5 ]
4-(N-(2-formylphenyl)sulfamoyl)phenyl pivalate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With pyridine; at 20℃; for 4h;	General procedure: Initially, phenol (10 mmol) was dissolved in acetonitrile. Themixture solution was slowly added 3,3-dimethylbutyryl chloride(1.5 equiv) at 0 C, and then stirred at room temperature for 12 h.The solvent was evaporated at reduced pressure. The residue waspurified by silica gel column chromatography using a mixture ofn-hexane and acetone to afford the phenyl pivalate. Subsequently,phenyl pivalate was dissolved in acetonitrile. The mixture solutionwas slowly added chlorosulfonic acid (1.5 equiv) at 0 C andreacted at 0 C for 15 min, and then refluxed at 75 C for 2 h. Thesolutions were quenched by ice; the resulting mixtures were filtrated;and the residues was purified by silica gel column chromatographyusing a mixture of n-hexane/ethyl acetate to afford<strong>[150374-99-5]4-(chlorosulfonyl)phenyl pivalate</strong> (Scheme 1). To a mixture solutionof 2-aminoacetophenone, 1-(2-aminophenyl)propan-1-one,1-(2-aminophenyl)butan-1-one, 1-(2-aminophenyl)pentan-1-one,or 2-aminobenzaldehyde (each 1.0 equiv) in pyridine, respectively,was added <strong>[150374-99-5]4-(chlorosulfonyl)phenyl pivalate</strong>, and then stirred atroom temperature for 4 h. The reaction mixture was concentratedand purified by silica gel column chromatography using a mixtureof n-hexane/acetone solutions, to afford the products (Scheme 2,1-5).

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

64
[ 7065-46-5 ]
[ 150374-99-5 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

65
[ 4920-92-7 ]
[ 150374-99-5 ]

Yield	Reaction Conditions	Operation in experiment
	With chlorosulfonic acid; In acetonitrile; at 0 - 75℃; for 2.25h;	Initially, phenol (10 mmol) was dissolved in acetonitrile. Themixture solution was slowly added 3,3-dimethylbutyryl chloride(1.5 equiv) at 0 C, and then stirred at room temperature for 12 h.The solvent was evaporated at reduced pressure. The residue waspurified by silica gel column chromatography using a mixture ofn-hexane and acetone to afford the phenyl pivalate. Subsequently,phenyl pivalate was dissolved in acetonitrile. The mixture solutionwas slowly added chlorosulfonic acid (1.5 equiv) at 0 C andreacted at 0 C for 15 min, and then refluxed at 75 C for 2 h. Thesolutions were quenched by ice; the resulting mixtures were filtrated;and the residues was purified by silica gel column chromatographyusing a mixture of n-hexane/ethyl acetate to afford4-(chlorosulfonyl)phenyl pivalate (Scheme 1). To a mixture solutionof 2-aminoacetophenone, 1-(2-aminophenyl)propan-1-one,1-(2-aminophenyl)butan-1-one, 1-(2-aminophenyl)pentan-1-one,or 2-aminobenzaldehyde (each 1.0 equiv) in pyridine, respectively,was added 4-(chlorosulfonyl)phenyl pivalate, and then stirred atroom temperature for 4 h. The reaction mixture was concentratedand purified by silica gel column chromatography using a mixtureof n-hexane/acetone solutions, to afford the products (Scheme 2,1-5).

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

66
[ 150374-99-5 ]
N-(2-acetylphenyl)-4-hydroxybenzenesulfonamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

67
[ 150374-99-5 ]
N-(2-formylphenyl)-4-hydroxybenzenesulfonamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

68
[ 150374-99-5 ]
4-(N-(2-acetylphenyl)sulfamoyl)phenyl 2-methylpropane-2-sulfinate [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

69
[ 150374-99-5 ]
4-(N-(2-formylphenyl)sulfamoyl)phenyl 2-methylpropane-2-sulfinate [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

70
[ 150374-99-5 ]
(E)-4-(N-(2-(1-(hydroxyimino)ethyl)phenyl)sulfamoyl)phenyl pivalate [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

71
[ 150374-99-5 ]
(E)-4-(N-(2-(1-(hydroxyimino)propyl)phenyl)sulfamoyl)phenyl pivalate [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

72
[ 150374-99-5 ]
(E)-4-(N-(2-(1-(hydroxyimino)butyl)phenyl)sulfamoyl)phenyl pivalate [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

73
[ 150374-99-5 ]
(E)-4-(N-(2-(1-(hydroxyimino)methyl)phenyl)sulfamoyl)phenyl pivalate [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

74
1-(2-aminophenyl)ethanone O-methyl oxime [ No CAS ]
[ 150374-99-5 ]
(E)-4-(N-(2-(1-(methoxyimino)ethyl)phenyl)sulfamoyl)phenyl pivalate [ No CAS ]
(Z)-4-(N-(2-(1-(methoxyimino)ethyl)phenyl)sulfamoyl)phenyl pivalate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
60%; 2.5%	With pyridine; at 20℃; for 4h;	B. Preparation of Compounds (5) and (6) (0120) The procedure for preparing Compounds (5) and (6) is similar to procedure A in Preparation Example 1. The difference resides in that 1-(2-aminophenyl)ethanone O-methyl oxime (0.5 mmol) was used to replace 2-aminoacetophenone (1 mmol). Compounds (5) and (6) were purified using a silica gel column (n-hexane/acetone=4:1), thereby obtaining Compound (5) of a white powder (242 mg, yield 60%) and Compound (6) of a white powder (10 mg, yield 2.5%). Structure Identification Compound (5): (0121) 1H NMR (400 MHz, CDCl3) delta: 10.77 (1H, s, NH), 7.69 (2H, d, J=8.8 Hz), 7.65 (1H, br. dd, J=1.2, 8.4 Hz), 7.30 (1H, br, td, J=1.2, 8.4 Hz), 7.27 (1H, d, J=8.4 Hz), 7.11 (1H, td, J=1.2, 8.4 Hz), 7.08 (2H, d, J=8.8 Hz), 4.06 (3H, s, OCH3), 2.02 (3H, s, CH3), 1.33 (9H, s, (CH3)3); 13C-NMR (CDCl3, 100 MHz) delta: 176.2 (s, -OCO-), 156.1 (s, C?N), 154.4 (s, C-4?), 136.4 (s, C-1?), 135.4 (s, C-2), 129.7 (d, C-6), 128.7 (d, C-2?, 6?), 128.5 (d, C-4), 125.0 (s, C-1), 124.5 (d, C-5), 122.3 (d, C-3?, 5?), 121.9 (d, C-3), 62.6 (q, OCH3), 39.2 (s, C(CH3)3), 27.0 (q, (CH3)3), 13.2 (q, CH3); ESI-MS: 403.4 ([M-H]-); HRESI-MS: m/z 403.1322 ([M-H]-) (calcd. for C20H23O5N2S, 403.1331). Compound (6): (0122) 1H NMR (400 MHz, CDCl3) delta: 7.66 (2H, d, J=8.8 Hz), 7.64 (1H, br. dd, J=1.2, 7.6 Hz), 7.40 (1H, td, J=1.2, 7.6 Hz), 7.23 (1H, td, J=1.2, 7.6 Hz), 7.10 (2H, d, J=8.8 Hz), 7.05 (1H, d, J=1.2, 7.6 Hz), 3.91 (3H, s, OCH3), 1.57 (3H, s, CH3), 1.36 (9H, s, (CH3)3); 13C-NMR (CDCl3, 100 MHz) delta: 176.3 (s, -OCO-), 154.6 (s, C?N), 153.6 (s, C-4?), 136.7 (s, C-1?), 132.7 (s, C-2), 130.3 (d, C-1), 130.1 (s, C-6), 128.8 (d, C-2?, 6?), 127.3 (d, C-4), 126.5 (d, C-3), 126.3 (d, C-3), 122.3 (d, C-3?, 5?), 62.1 (q, OCH3), 39.2 (s, C(CH3)3), 27.0 (q, (CH3)3), 21.3 (q, CH3); ESI-MS: 427.1 ([M+Na]+); HRESI-MS: m/z 427.1298 ([M+Na]+) (calcd. for C18H20N2O5SNa, 427.1294).
	With pyridine; for 4h;	General procedure: To a mixture solution of compounds 1-3 or 5 (each 1 equiv) inethanol, respectively, was added hydroxylamine hydrochloride(1.5 equiv), and refluxed for 14 h.27 The reaction mixture was concentratedand purified by silica gel column chromatography usinga mixture of n-hexane/acetone (4:1 or 5:1) solutions, to affordcompounds 6-8, and 11 (Scheme 2).To a mixture solution of 2-aminoacetophenone (1 equiv) in ethanolwas added methoxylamine hydrochloride (1.5 equiv), andrefluxed for 12 h.27 The reaction mixture was concentrated, partitionedin dichloromethane and water, and gave the 1-(2-aminophenyl)ethanone O-methyl oxime. Subsequently, 1-(2-aminophenyl)ethanone O-methyl oxime was dissolved in pyridine,and added <strong>[150374-99-5]4-(chlorosulfonyl)phenyl pivalate</strong>. The mixture solutionwas stirred for 4 h at room temperature, and then purified by silicagel column chromatography using a mixture of n-hexane/acetone(4:1) solutions, to afford compounds 9 and 10 (Scheme 3).

Reference： [1]Patent: US9073833,2015,B1 .Location in patent: Page/Page column 11-12; 16-17
[2]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 1123 - 1134

75
(E)-1-(2-aminophenyl)ethanone O-3-hydroxypropyl oxime [ No CAS ]
[ 150374-99-5 ]
(E)-4-(N-(2-(1-(3-hydroxypropoxyimino)ethyl)phenyl)sulfamoyl)phenyl pivalate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
49%	With pyridine; In dichloromethane; for 16h;Reflux;	C. Preparation of Compound (7) (0126) (E)-1-(2-aminophenyl)ethanone O-3-hydroxypropyl oxime (0.2 mmol) was added into dichloromethane (DCM) (5 mL), followed by adding pyridine (10 equivalent weights) and <strong>[150374-99-5]4-(chlorosulfonyl)phenyl pivalate</strong> (2 equivalent weights) therein to obtain a mixture. The mixture was heated under reflux for 16 hours and was purified using a silica gel column (n-hexane/acetone=6:1), thereby obtaining Compound (7) of a white powder (43 mg, yield 49%). Structure Identification (0127) 1H-NMR (CDCl3, 400 MHz) delta: 10.82 (1H, s, NH), 7.71 (2H, br. dd, J=8.8 Hz, H-3?, 5?), 7.63 (1H, dd, J=1.2, 8.0 Hz, H-3), 7.33 (1H, dd, J=1.2, 8.0 Hz, H-6), 7.28 (1H, td, J=1.2, 8.0 Hz, H-5), 7.09 (2H, d, J=8.8 Hz, H-2?, 6?), 7.10 (1H, td, J=1.2, 8.0 Hz, H-4), 4.39 (2H, t, J=6.4 Hz, ?NOCH2-), 3.82 (2H, t, J=6.0 Hz, -CH2OH), 3.82 (2H, t, J=6.0 Hz, -CH2OH), 2.06 (2H, m, CH2), 2.06 (3H, s, CH3), 1.33 (9H, s, (CH3)3); 13C-NMR (CDCl3, 100 MHz) delta: 176.3 (s, -OCO-), 156.2 (s, C?N), 154.4 (s, C-4?), 136.4 (s, C-2), 135.4 (s, C-1?), 129.7 (d, C-4), 128.6 (d, C-6), 128.6 (d, C-2?, 6?), 124.8 (d, C-5), 124.4 (s, C-1), 122.0 (d, C-3?, 5?), 121.7 (d, C-3), 72.1 (t, ?NOCH2-), 59.8 (-CH2OH), 39.2 (s, C(CH3)3), 32.2 (t, CH2), 27.0 (q, (CH3)3), 13.3 (q, CH3); ESI-MS: 449.2 ([M+H]+), 471.2 ([M+Na]+); HRESI-MS: m/z 449.1761 ([M+H]+) (calcd. for C22H29N2O6S, 449.1741).

Reference： [1]Patent: US9073833,2015,B1 .Location in patent: Page/Page column 18

76
[ 551-93-9 ]
[ 150374-99-5 ]
(E)-4-(N-(2-(1-(hydroxyimino)ethyl)phenyl)sulfamoyl)phenyl pivalate [ No CAS ]

Reference： [1]Patent: US9073833,2015,B1

77
[ 3282-30-2 ]
[ 150374-99-5 ]

Reference： [1]Patent: JP5746484,2015,B2

78
[ 3282-30-2 ]
[ 825-90-1 ]
[ 150374-99-5 ]

Yield	Reaction Conditions	Operation in experiment
81.1%		Sodium 4-hydroxybenzenesulfonate (3) (1.0 g, 0.0049 mol),Addition of a solution of DCM (6 ml) and TEA (1.0 g, 0.0098 mol) in pivaloyl chloride (0.84 g, 0.0069 mol) is carried out dropwise at 20-25 C. under magnetic stirring in about 5 minutes. The mixtureContinue stirring at 20-25 C for 2 hours while monitoring with HPLC. After completion of the reaction,DMF (0.11 g, 0.0015 mol) was added,Thionyl chloride (0.77 g, 0.0064 mol) is added dropwise at 20-25 C. over 15 minutes. The mixtureWhile monitoring by HPLC,Stirring is continued for 2 hours at this temperature. After completion of the reaction,The solvent was removed by evaporation under reduced pressure,Toluene (10 ml) was added,The salt was filtered off,The solvent is concentrated under reduced pressure. To the resulting residue,5 ml of n-hexane was added,next,It was cooled to 0 C.,The resulting suspension is filtered,Wash the product with n-hexane. 1.1 g of a pale yellow solid (81.1%).

Reference： [1]Patent: JP5746484,2015,B2 .Location in patent: Paragraph 0003; 0006; 0009; 0015; 0036; 0037

79
[ 150374-99-5 ]
sodium N-[2-[4-(2,2-dimethylpropionyloxy)phenylsulfonyl amino]benzoyl]aminoacetate [ No CAS ]

Reference： [1]Patent: JP5746484,2015,B2

80
[ 96-35-5 ]
[ 150374-99-5 ]
4-((2-methoxy-2-oxoethoxy)sulfonyl)phenyl pivalate [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2018,vol. 83,p. 4323 - 4335

81
[ 150374-99-5 ]
methyl 2-(((4-hydroxyphenyl)sulfonyl)oxy)acetate [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2018,vol. 83,p. 4323 - 4335

82
[ 150374-99-5 ]
methyl 2-(((4-(3-azidopropoxy)phenyl)sulfonyl)oxy)acetate [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2018,vol. 83,p. 4323 - 4335

83
[ 150374-99-5 ]
2-(((4-(3-azidopropoxy)phenyl)sulfonyl)oxy)acetic acid [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2018,vol. 83,p. 4323 - 4335

84
[ 29879-48-9 ]
[ 150374-99-5 ]
4-((3-methyl-5-oxo-4-phenylisoxazol-2(5H)-yl)sulfonyl)phenyl pivalate [ No CAS ]

Reference： [1]Journal of Enzyme Inhibition and Medicinal Chemistry,2018,vol. 33,p. 1108 - 1124

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 150374-99-5 ]

Aryls

[ 56077-78-2 ]

Methyl 2-(4-(chlorosulfonyl)phenoxy)acetate

Similarity: 0.82

[ 58076-32-7 ]

4-Propoxybenzene-1-sulfonyl chloride

Similarity: 0.79

[ 17641-39-3 ]

2-(4-(Chlorosulfonyl)phenoxy)acetic acid

Similarity: 0.78

[ 1138-56-3 ]

4-Butoxybenzene-1-sulfonyl chloride

Similarity: 0.77

[ 1132-17-8 ]

4-Ethoxybenzene-1-sulfonyl chloride

Similarity: 0.76

Sulfonyl Chlorides

[ 56077-78-2 ]

Methyl 2-(4-(chlorosulfonyl)phenoxy)acetate

Similarity: 0.82

[ 58076-32-7 ]

4-Propoxybenzene-1-sulfonyl chloride

Similarity: 0.79

[ 17641-39-3 ]

2-(4-(Chlorosulfonyl)phenoxy)acetic acid

Similarity: 0.78

[ 1138-56-3 ]

4-Butoxybenzene-1-sulfonyl chloride

Similarity: 0.77

[ 1132-17-8 ]

4-Ethoxybenzene-1-sulfonyl chloride

Similarity: 0.76

Chlorides

[ 56077-78-2 ]

Methyl 2-(4-(chlorosulfonyl)phenoxy)acetate

Similarity: 0.82

[ 58076-32-7 ]

4-Propoxybenzene-1-sulfonyl chloride

Similarity: 0.79

[ 17641-39-3 ]

2-(4-(Chlorosulfonyl)phenoxy)acetic acid

Similarity: 0.78

[ 1138-56-3 ]

4-Butoxybenzene-1-sulfonyl chloride

Similarity: 0.77

[ 1132-17-8 ]

4-Ethoxybenzene-1-sulfonyl chloride

Similarity: 0.76

Esters

[ 56077-78-2 ]

Methyl 2-(4-(chlorosulfonyl)phenoxy)acetate

Similarity: 0.82

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 150374-99-5 ] {[proInfo.proName]}

Quality Control of [ 150374-99-5 ]

Related Doc. of [ 150374-99-5 ]

Product Details of [ 150374-99-5 ]

Calculated chemistry of [ 150374-99-5 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 150374-99-5 ]

Application In Synthesis of [ 150374-99-5 ]

[ 150374-99-5 ] Synthesis Path-Upstream 1~6

[ 150374-99-5 ] Synthesis Path-Downstream 1~84

Related Functional Groups of [ 150374-99-5 ]

Aryls

Sulfonyl Chlorides

Chlorides

Esters

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 150374-99-5 ]